| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cerus Corporation | INTERCEPT (ReCePI) | Patients undergoing complex cardiac surgery procedures | Phase 3 | Trial Completed | Intravenous | Cardiology |
| Cerus Corporation | INTERCEPT | Chronic anemia in thalassemia patients | Phase 3 | Trial Completed | Intravenous | Hematology |
| CervoMed Inc. | Trans Sodium Crocetinate (TSC) - (Study 200-208) | Glioblastoma (GBM) | Phase 2 | Trial Planned | Intravenous | Oncology |
| CervoMed Inc. | Trans sodium crocetinate (TSC) | Hypoxic solid tumors | Phase 2 | Trial Planned | Intravenous | Oncology |
| CervoMed Inc. | Trans Sodium Crocetinate (TSC) | Interstitial Lung Disease (ILD) | Phase 2 | Trial Discontinued | Intravenous | Respiratory |
| CervoMed Inc. | Trans sodium crocetinate (TSC) | Glioblastoma (GBM) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| CervoMed Inc. | Neflamapimod - (AscenD-LB) | Dementia with Lewy bodies (DLB) | Phase 2a | Data Released | Oral | Neurology |
| CervoMed Inc. | Trans sodium crocetinate (TSC) - (PHAST-TSC) | Ischemic or hemorrhagic stroke | Phase 2 | Trial Discontinued | Intravenous | Neurology |